Target healthy cells to stop brain cancer 'hijack': UBC study
2015-08-12
(Press-News.org) New UBC research into brain cancer suggests treatments should target the cells around a tumor to stop it from spreading.
UBC research team Christian Naus, Wun Chey Sin and John Bechberger study glioma, the most aggressive form of adult brain cancer. Glioma has a low five-year survival rate of 30 per cent because it is difficult to completely remove cancer cells without compromising brain functions and chemotherapy and radiotherapy do not prevent the regrowth of remaining cancer cells.
With this new research, the team reveals an alternative route to rein in the glioma cancer cells. The cancerous cells mingle with astrocytes, a type of cell that regulates the environment in the brain to create favourable conditions for brain functions. The research team found that glioma cells can reprogram the astrocytes with little pieces of genetic code (microRNAs). Those codes act as master switches, turning specific sets of genes on and off.
"This is the first evidence that microRNA can go from glioma cells into astrocytes and reprogram them to provide an altered environment that stimulates tumor growth and invasion," said Naus, a professor in the Department of Cellular & Physiological Sciences in the Life Sciences Institute and an investigator with the Djavad Mowafaghian Centre for Brain Health.
"We should consider the possibility of creating a treatment that would temporarily modify the healthy astrocytes around the tumor so the cancer cells can't hijack them," said Sin, a research associate leading the glioma investigation in the Naus laboratory.
The findings were recently published in three related papers in the journals Oncogene and Oncotarget.
INFORMATION:
The research was also highlighted in a recent interdisciplinary project, "Fashioning Cancer: A Correlation Between Destruction and Beauty," where images of brain cancer were used to highlight public awareness, as well as raise funds for cancer research.
Publications
Astrocytes promote glioma invasion via the gap junction protein connexin43.
Sin WC, Aftab Q, Bechberger JF, Leung JH, Chen H, Naus CC.
Oncogene. 2015 Jul 13. doi: 10.1038/onc.2015.210. [Epub ahead of print]
PMID: 26165844
Gap junctions modulate glioma invasion by direct transfer of microRNA
Hong X, Sin WC, Harris AL, Naus CC.
Oncotarget. 2015 May 4. [Epub ahead of print]
PMID: 25978028
Reduction in gap junction intercellular communication promotes glioma migration
Aftab Q, Sin WC, Naus CC.
Oncotarget. 2015 May 10;6(13):11447-64.
PMID: 25926558
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2015-08-12
Researchers at New Zealand's University of Otago have discovered why heart disease is the number-one killer of people with diabetes, a breakthrough finding opening the way for new treatments to combat the disease in diabetic patients by targeting a key protein called Beclin-1.
Diabetes affects more than 365 million people worldwide with rates expected to double by 2030. Recent studies show that at least 60% of people with the disease die because of cardiovascular complications.
Why diabetes takes such a toll on heart health has long remained a mystery. Now, in a new ...
2015-08-12
The U.S. Food and Drug Administration recently approved the first new drug to fight tuberculosis (TB) in more than 40 years, but treatment still takes six months, 200 pills and leaves 40 percent of patients uncured. Thus, new targets are needed. Today in ACS Central Science, researchers report they have identified one such target -- a gene that allows the disease to camp out in human immune cells, and is thus essential for the organism's proliferation.
TB kills about 1.3 million people around the world every year. The microorganism that causes the disease, Mycobacterium ...
2015-08-12
IVF success rates for women aged 43 and above could improve by retrieving eggs from their ovaries at an earlier stage of fertility treatment, according to a new study published today in the Journal of Endocrinology.
US-based researchers found that the function of cells which nurse and support the development of eggs declines rapidly after 43, causing the egg to be bombarded by hormones that are normally only released after ovulation. Retrieving eggs from smaller follicles at an earlier stage in the IVF process was found to minimise this risk, resulting in a higher quality ...
2015-08-12
August 12, 2015--(BRONX, NY)--Using real-time, high-resolution imaging, scientists have identified how a "doorway" in the blood vessel wall allows cancer cells to spread from breast tumors to other parts of the body. The findings lend support to emerging tests that better predict whether breast cancer will spread, which could spare women from invasive and unnecessary treatments, and could lead to new anti-cancer therapies. The research, conducted by investigators at the NCI-designated Albert Einstein Cancer Center (AECC) and Montefiore Einstein Center for Cancer Care, utilized ...
2015-08-12
CLEVELAND, Ohio (August 12, 2015)--Local vaginal estrogen (VE) appears to have escaped the shroud of doubt cast upon hormone therapy as a result of the Women's Health Initiative Study (WHI) by providing numerous medical benefits without systemic effects. That's according to a new study reported online today in Menopause, the journal of The North American Menopause Society (NAMS).
The study demonstrated that postmenopausal women who suffer from painful intercourse and vaginal dryness are more likely to use VE, regardless of whether they use any other type of hormone therapy. ...
2015-08-11
Cost of radiation therapy among Medicare patients varied most widely because of factors unrelated to a patient or that person's cancer, report University of California, San Diego School of Medicine researchers in the Journal of Oncology Practice.
Year of diagnosis, location of treatment, clinic type and individual radiation provider accounted for 44 to 61 percent of the variation in cost for patients with breast, lung and prostate cancer therapies, according to the study published August 11 online. Factors associated with the patient or patient's tumor accounted for less ...
2015-08-11
Birds of a feather may flock together, but that doesn't mean they share a genetic background. Though birds were first classified into groups primarily based on appearance, research forthcoming in The Auk: Ornithological Advances by Brett Benz of the American Museum of Natural History, Mark Robbins of the University of Kansas Biodiversity Institute, and Kevin Zimmer of the Los Angeles County Museum of Natural History demonstrates that this method isn't necessarily accurate: in a group of very similar-looking South American woodpecker species, genetic analysis has now shown ...
2015-08-11
The immune system not only responds to infections and other potentially problematic abnormalities in the body, it also contains a built-in brake in the form of regulatory T cells, or Tregs. Tregs ensure that inflammatory responses don't get out of hand and do damage. In autoimmune diseases, sometimes these Treg cells don't act as they should.
A new study led by Songtao Shi of the University of Pennsylvania has demonstrated how Tregs can themselves be regulated, by an unexpected source: hydrogen sulfide, a gas produced by the body's muscle cells and one often associated ...
2015-08-11
MADISON, Wis. -- Graphene, an atom-thick material with extraordinary properties, is a promising candidate for the next generation of dramatically faster, more energy-efficient electronics. However, scientists have struggled to fabricate the material into ultra-narrow strips, called nanoribbons, that could enable the use of graphene in high-performance semiconductor electronics.
Now, University of Wisconsin-Madison engineers have discovered a way to grow graphene nanoribbons with desirable semiconducting properties directly on a conventional germanium semiconductor wafer. ...
2015-08-11
(SACRAMENTO, Calif.) -- In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.
Led by Emanual Maverakis of the UC Davis Department of Dermatology, the research found that Interleukin (IL)-2 combined with imiquimod and topical retinoid therapy in patients with so-called "in-transit metastases" is a promising therapeutic option.
The findings have been published online first in the Journal of the American Academy of Dermatology (doi:10.1016/j.jaad.2015.06.060).
"It's ...
LAST 30 PRESS RELEASES:
[Press-News.org] Target healthy cells to stop brain cancer 'hijack': UBC study
